Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets

Pathology and Oncology Research

Volumn 21, Issue 3, 2015, Pages 695-701

  Wu, Hao ^a,b   Sun, Yue ^b   Ye, Huihui ^c   Yang, Shi ^b   Lee, Stephanie L ^b   de las Morenas, Antonio ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anaplastic thyroid cancer; BRAF; c KIT; PDL1; Targeted therapy

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; STEM CELL FACTOR RECEPTOR; BRAF PROTEIN, HUMAN; CD274 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P21; TUMOR MARKER;

ADULT; AGED; ANAPLASTIC THYROID CANCER; ARTICLE; BRAF GENE; CANCER SURVIVAL; CODON; CONTROLLED STUDY; EGFR GENE; EXON; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONCOGENE K RAS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; WILD TYPE; ADENOCARCINOMA; CANCER STAGING; FOLLOW UP; GENETICS; METABOLISM; METASTASIS; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; THYROID CARCINOMA; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; ANTIGENS, CD274; BIOMARKERS, TUMOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS;

EID: 84939416350     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9876-5     Document Type: Article

References (38)

1. Carling T, Udelsma R (2008) Thyroid tumors. In: DeVita VT, Lawrence TS, Rosenberg SA (eds) Devita, Hellman & Rosenberg’s cancer [electronic resource]: principles and practice of oncology. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, pp 1663–1682
2. Edge SB, Byrd DR, Compton CC et al. (eds) (2010) AJCC cancer staging handbook. 7th ed. New York, NY: Springer New York
3. Sugitani I, Miyauchi A, Sugino K et al (2012) Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC research consortium of Japan cohort Study of 677 patients. World J Surg 36:1247–1254
4. Kebebew E, Greenspan FS, Clark OH et al (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330–1335
5. Busnardo B, Daniele O, Pelizzo MR et al (2000) A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Investig 23:755–761
6. Pierie J-PEN, Muzikansky A, Gaz RD et al (2002) The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9:57–64
7. Haigh PI, Ituarte PH, Wu HS et al (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335–2342
8. Smallridge RC (2012) Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 97:2566–2572
9. Akaishi J, Sugino K, Kitagawa W et al (2011) Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid: Off J Am Thyroid Assoc 21:1183–1189
10. Nehs MA, Nagarkatti S, Nucera C et al (2010) Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery 148:1154–1162, discussion 1162
11. Gule MK, Chen Y, Sano D et al (2011) Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 17:2281–2291
12. Nobuhara Y, Onoda N, Yamashita Y et al (2005) Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 92:1110–1116
13. Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306
14. Sipos JA, Shah MH (2010) Thyroid cancer: emerging role for targeted therapies. Ther Adv Med Oncol 2:3–16
15. Antonelli A, Fallahi P, Ferrari SM et al (2012) RET TKI: potential role in thyroid cancers. Curr Oncol Rep 14:97–104
16. Keir ME, Butte MJ, Freeman GJ et al (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704
17. Brahmer JR, Tykodi SS, Chow LQM et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465
18. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:1–12
19. Hong DS, Kurzrock R, Supko JG et al (2012) A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res 18:3396–3406
20. Yang S, Farraye FA, Mack C et al (2004) BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 28:1452–1459
21. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954
22. Pollock PM, Harper UL, Hansen KS et al (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19–20
23. Amado RG, Wolf M, Peeters M et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
24. Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230–3237
25. Pan Q, Pao W, Ladanyi M (2005) Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn JMD 7:396–403
26. Pinter F, Papay J, Almasi A et al (2008) Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn JMD 10:160–168
27. Oh Y-H, Kim Y, Kim Y-P et al (2010) Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons. J Mol Diagn JMD 12:644–652
28. Gupta-Abramson V, Troxel AB, Nellore A et al (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714–4719
29. Kloos RT, Ringel MD, Knopp MV et al (2009) Phase II trial of Sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675–1684
30. Pennell NA, Daniels GH, Haddad RI et al. (2008) A phase II study of gefitinib in patients with advanced thyroid cancer
31. Elliott DD, Sherman SI, Busaidy NL et al (2008) Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol 39:15–20
32. Lee DH, Lee GK, Kong S et al (2007) Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol 60:881–884
33. Fisher KE, Jani JC, Fisher SB et al (2013) Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. J Surg Res. doi:10.1016/j.jss.2013.05.003
34. Schoenfeld JD, Odejide OO, Wirth LJ et al (2012) Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib — a case report. Anticancer Res 32:1743–1746
35. Bible KC, Suman VJ, Molina JR et al. (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
36. Bible KC, Suman VJ, Menefee ME et al (2012) A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 97:3179–3184
37. Ha HT, Lee JS, Urba S et al (2010) A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid Off J Am Thyroid Assoc 20:975–980
38. Kimura H, Nakajima T, Takeuchi K et al (2012) ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. Lung Cancer 75:66–72